Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
AIDS and HIV
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - AIDS and HIV
    Percutaneous Coronary Intervention Safe in Patients Infected With HIV: Presented at AHA - (DGDispatch)
    Extensively drug-resistant tuberculosis in the United States, 1993-2007 - (JAMA)
    TopAbstracts in AIDS and HIV 11/10/2008 - (DGNews)
    HIV Drug Etravirine Does Not Appear to Cause Hepatotoxicity: Presented at AASLD - (DGDispatch)
    AAP Statement Recommends Prenatal Testing, Immediate Intervention to Prevent Mother-to-Child HIV Transmission - (DGNews)

    News archive

     Recent webcasts/CME - AIDS and HIV

    Webcasts/CME archive

     Recent cases - AIDS and HIV
      Soft Tissue Non-Hodgkin Lymphoma of Shoulder in a HIV Patient: A Report of a Case and Review of the Literature
      HIV, Visceral Leishmaniasis and Parkinsonism Combined with Diabetes Mellitus and Hyperuricaemia: A Case Report
      Primary Kaposi Sarcoma of the Subcutaneous Tissue
      Primary Malignant Melanoma of the Esophagus With Separate Foci of Melanoma In Situ and Atypical Melanocytic Hyperplasia in a Patient Positive for Human Immunodeficiency Virus: A Case Report and Review of the Literature
      HIV-2 Diagnosis and Quantification in High-Risk Patients

      Cases archive
        




      my personal edition > aids and hiv > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Long-Term Indinavir Treatment Keeps HIV Under Control at 156 Weeks: Presented at IDSA

      By Ed Susman

      SAN FRANCISCO, CA -- October 11, 2005 -- Most patients who were treated with an antiretroviral regimen that included the protease inhibitor indinavir were able to maintain virologic control for at least 156 weeks.

      "Combination antiretroviral therapy with indinavir can yield long-term virologic and immunologic benefits for many treatment-naive asymptomatic patients with early HIV infection," said Deborah McMahon, MD, associate professor of medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

      Dr. McMahon presented the findings in a poster session here on October 8th at the 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA).

      In a trial that began in 1997, Dr. McMahon and colleagues placed 199 patients on the following protease inhibitor regimen:

      - Indinavir 800 mg TID, taken on an empty stomach with adequate fluids.
      - Zidovudine 300 mg every 12 hours.
      - Lamivudine 150 mg every 12 hours.
      - Stavudine (30 mg or 40 mg depending on body weight) every 12 hours. Could be substituted for zidovudine in case of intolerance.
      - Ritonavir 100 mg every 12 hours, added to the regimen after 96 weeks of treatment.

      After 24 weeks, 95% of the 174 evaluable patients had achieved viral suppression to an undetectable level using the 400-copy/mL assay, and 91% had achieved undetectable virus on the 50-copy/mL assay.

      After 156 weeks of treatment, 114 of the participants (about 57% of the original group) were still on the regimen.

      Dr. McMahon said that about 15% of participants left the study due to adverse effects. About 5% of serious adverse events were considered by the investigators to be related to treatment. One person died during the study.


      [Presentation title: Long-Term Efficacy, Safety and Tolerability of Indinavir-Based Combination Therapy in Treatment-Naïve Adults With Early HIV Infection. Abstract 798]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send